Today's Date
Daratumumab in Primary Antiphospholipid Syndrome
(
DARE-APS
)
ITN Protocol #:
ITN093AI
Branded Name:
DARE-APS
ClinicalTrials.Gov ID:
NCT05671757Treatment Protocol #:
Therapeutic Area:
Autoimmune Disease
Current Status:
Enrollment
Summary:
Targeting CD38 with Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial
Clinical Operations Manager
ITN Biologist
Study Personnel:
